InMed Pharmaceuticals Announces Standby Equity Purchase Agreement

Introduction

Vancouver, British Columbia–(Newsfile Corp. – December 17, 2024) – InMed Pharmaceuticals Inc. (NASDAQ: INM) (“InMed” or the “Company”), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, announces it entered into a Standby Equity Purchase Agreement (the “SEPA”) with YA II PN, LTD (the “Investor”), an investment fund managed by Yorkville Advisors Global LP, a global investment manager, on December 13, 2024 (the “Effective Date”) to sell up to $10 million in the aggregate of the Company’s common shares, no value (the “Common Shares”), at any time during the 36-month period following the Effective Date of the SEPA, subject to the effectiveness of a registration statement with the Securities and Exchange Commission and other conditions set forth in the SEPA.

Details of the Agreement

This equity facility is a key component of our financing strategy, offering both flexibility and extended runway to accelerate our pharmaceutical programs and other business development initiatives,” said Eric A.

Impact on Individuals

Based on other online sources, this agreement could potentially lead to increased funding and resources for InMed Pharmaceuticals, ultimately allowing them to develop new drug candidates to address unmet medical needs. This could potentially lead to the development of new treatments for various diseases, providing hope for individuals affected by these conditions.

Global Impact

On a global scale, this agreement could have far-reaching implications in the pharmaceutical industry. By providing funding for the development of new drug candidates, InMed Pharmaceuticals could potentially contribute to advancements in medical science and improve healthcare outcomes for populations around the world. This could lead to a ripple effect in the industry, potentially inspiring other companies to invest in similar research and development initiatives.

Conclusion

In conclusion, the Standby Equity Purchase Agreement between InMed Pharmaceuticals and YA II PN, LTD has the potential to significantly impact both individuals and the world at large. By providing funding for the development of new drug candidates, this agreement could lead to important advancements in the field of medicine and potentially improve the lives of individuals affected by various diseases. Ultimately, this represents a positive step forward in the pursuit of innovative healthcare solutions.